# CORE-008 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/core-008

> CORE-008, sponsored by CG Oncology, Inc. (CGON): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CORE-008 |
| Codes | CORE-008 |
| Sponsor | CG Oncology, Inc. (CGON) https://sec-api.dev/companies/cgon/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | breakthrough, fast track |

## Timeline

### Oct 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-28, last confirmed 2026-11-06.
- SEC Form 10-Q (accession 0001991792-26-000012): "In October 2024, we initiated CORE-008 Cohort A, a Phase 2 clinical trial in high-risk NMIBC patients who are naïve to BCG treatment, including patients with CIS and with or without papillary disease and patients with only papillary disease." https://www.sec.gov/Archives/edgar/data/1991792/000199179226000012/ck0001991792-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-336918): "In October 2024, we initiated CORE-008 Cohort A, a Phase 2 clinical trial in high-risk NMIBC patients who are naïve to BCG treatment, including patients with CIS and with or without Ta/T1 disease and patients with only Ta/T1 disease." https://www.sec.gov/Archives/edgar/data/1991792/000119312526336918/ck0001991792-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-214669): "In October 2024, we initiated CORE-008 Cohort A, a Phase 2 clinical trial in high-risk NMIBC patients who are naïve to BCG treatment, including patients with CIS and with or without Ta/T1 disease and patients with only Ta/T1 disease." https://www.sec.gov/Archives/edgar/data/1991792/000119312526214669/ck0001991792-20260331.htm
- SEC Form 10-K (accession 0001193125-26-079498): "In October 2024, we initiated CORE-008 Cohort A, a Phase 2 clinical trial in high-risk NMIBC patients who are naïve to BCG treatment, including patients with CIS and with or without Ta/T1 disease and patients with only Ta/T1 disease." https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-283000): "In October 2024, we initiated CORE-008 Cohort A, our Phase 2 clinical trial in high-risk NMIBC patients who are naïve to BCG treatment, including patients with CIS and with or without Ta/T1 disease and patients with only Ta/T1 disease." https://www.sec.gov/Archives/edgar/data/1991792/000119312525283000/ck0001991792-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-105855): "In October 2024, we initiated CORE-008 Cohort A, our Phase 2 clinical trial in high-risk NMIBC patients who are naïve to BCG treatment, including patients with CIS and with or without Ta/T1 disease and patients with only Ta/T1 disease." https://www.sec.gov/Archives/edgar/data/1991792/000095017025105855/ck0001991792-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-069831): "In October 2024, we initiated CORE-008 Cohort A, our Phase 2 clinical trial in high-risk NMIBC patients who are naïve to BCG treatment, including patients with CIS and with or without Ta/T1 disease and patients with only Ta/T1 disease." https://www.sec.gov/Archives/edgar/data/1991792/000095017025069831/ck0001991792-20250331.htm
- SEC Form 10-K (accession 0000950170-25-046351): "In October 2024, we initiated CORE-008 Cohort A, our Phase 2 clinical trial in high-risk NMIBC patients who are naïve to BCG treatment, including patients with CIS and with or without Ta/T1 disease and patients with only Ta/T1 disease." https://www.sec.gov/Archives/edgar/data/1991792/000095017025046351/ck0001991792-20241231.htm

### late 2025: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-03-28, last confirmed 2025-03-28.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-046335): ""Looking ahead, further readouts are expected from our BOND-003 trial and the anticipated initiation of our Biologics License Application (BLA) submission, as well as the announcement of topline data from CORE-008 Cohort A expected before year-end."" https://www.sec.gov/Archives/edgar/data/1991792/000095017025046335/ck0001991792-ex99_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/core-008.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CORE-008 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/core-008

```bibtex
@misc{secapidev_pdufa_core_008_20261116,
  title        = {CORE-008 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/core-008}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_core_008_20261116","title":"CORE-008 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/core-008","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
